Literature DB >> 7753547

Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6.

N J Marston1, J R Jenkins, K H Vousden.   

Abstract

The tumour suppressor protein p53 normally functions as a tetramer in a defined conformational state. Mutations within p53 which contribute to cancer development frequently induce a conformational shift in the protein which correlates with loss of wild type growth suppressor functions. Both the cell encoded mdm2 protein and the human papillomavirus oncoprotein E6 can regulate p53 function and we have examined the interaction of these proteins with p53. The E6/p53 association is sensitive to conformational alterations in the p53 protein, although oligomerisation is not necessary for this interaction to occur. Analysis of C-terminal p53 truncations has indicated that the region between residues 327 and 347 may play a role in E6 binding. Since monomeric forms of p53 retain transcriptional and transformation suppressor activities, our results indicate that E6 targets p53 proteins which retain these wild type functions. Conversely, the interaction of p53 with mdm2 is not dependent on the conformation of the p53 protein but is significantly impaired by loss of quaternary structure. It is possible that mdm2 plays a role in mediating activities of p53 which, unlike transcriptional activation, depend on oligomerisation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7753547

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

Review 1.  Mdm2: the ups and downs.

Authors:  T Juven-Gershon; M Oren
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

2.  Ubiquitination and degradation of mutant p53.

Authors:  Natalia Lukashchuk; Karen H Vousden
Journal:  Mol Cell Biol       Date:  2007-10-01       Impact factor: 4.272

3.  Regulation of Mdm2-directed degradation by the C terminus of p53.

Authors:  M H Kubbutat; R L Ludwig; M Ashcroft; K H Vousden
Journal:  Mol Cell Biol       Date:  1998-10       Impact factor: 4.272

4.  Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability.

Authors:  M H Kubbutat; K H Vousden
Journal:  Mol Cell Biol       Date:  1997-01       Impact factor: 4.272

5.  Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.

Authors:  R Ravi; B Mookerjee; Z M Bhujwalla; C H Sutter; D Artemov; Q Zeng; L E Dillehay; A Madan; G L Semenza; A Bedi
Journal:  Genes Dev       Date:  2000-01-01       Impact factor: 11.361

6.  DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization.

Authors:  S Y Shieh; Y Taya; C Prives
Journal:  EMBO J       Date:  1999-04-01       Impact factor: 11.598

7.  Destabilizing missense mutations in the tumour suppressor protein p53 enhance its ubiquitination in vitro and in vivo.

Authors:  Harumi Shimizu; David Saliba; Maura Wallace; Lee Finlan; Patrick R R Langridge-Smith; Ted R Hupp
Journal:  Biochem J       Date:  2006-07-15       Impact factor: 3.857

8.  Nucleolar protein GLTSCR2 stabilizes p53 in response to ribosomal stresses.

Authors:  S Lee; J-Y Kim; Y-J Kim; K-O Seok; J-H Kim; Y-J Chang; H-Y Kang; J-H Park
Journal:  Cell Death Differ       Date:  2012-04-20       Impact factor: 15.828

9.  Regulation of p53 function and stability by phosphorylation.

Authors:  M Ashcroft; M H Kubbutat; K H Vousden
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

10.  The p53 isoforms are differentially modified by Mdm2.

Authors:  Suzanne Camus; Sergio Ménendez; Kenneth Fernandes; Nelly Kua; Geng Liu; Dimitris P Xirodimas; David P Lane; Jean-Christophe Bourdon
Journal:  Cell Cycle       Date:  2012-04-15       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.